Making the undruggable druggable
After decades of research by the global academic community, Quintrigen is on the road to reignite mutant p53 protein, putting it back to work. We are guided by an exceptional team of world-renowned scientists from the Weizmann Institute in Israel, backed by BL (former, BioLeaders) of Korea, and we are taking a new strategy to reignite p53’s activity. By transforming it from mutant to normal again, we expect to impact the lives of millions of cancer patients worldwide.
Our Team
Orna Palgi, PhD
CEO
Orna Palgi, PhD
CEO
Orna is a seasoned pharmaceutical and biotechnology drug development executive and team leader, with over 20 years of experience at Teva Pharmaceutical Industries (Nasdaq and TASE: TEVA), Pharmos (Nasdaq: PARS), and OticPharma (Nasdaq: NVUS). In her last position at Teva, Dr. Palgi served as due diligence senior director supporting license-in of innovative potential drugs. Prior to that, Orna served as the CEO of OticPharma, a pharmaceutical start-up company in the field of Ear, Nose and Throat. Orna has a hands-on approach in all aspects of project management. Orna holds a PhD in Immunology from the Weizmann Institute in Israel.
Contact details: [email protected]
Board of Directors
Park Young Chul (Andy Park)
Chairman of the Board
Bernard K. Ham
Board Member
Park Young Chul (Andy Park)
Chairman of the Board
Dr. Park Young Chul is both the current chairman of BL Group and the CEO of BL Corp. He holds a doctorate at the Department of Public Administration at Yonsei University Graduate School and completion of the Global Negotiation and Mediation Program (GNMP) at Seoul National University. He went on as the head of the overseas business division, directly under the CEO, at Daewoo Group and served as the representative of the Korean and Asian subsidiaries of Lion Bridge Inc. (listed on NASDAQ in the US) and SDL Inc. (listed on the London Stock Exchange, UK). He founded BL Science Corp. (Diagnostic company) which whom served as CEO and acquired BL Corp. (new drug development company), BL Pharmtech Corp. (Pharmaceutical company), and BL Healthcare Corp.(Healthcare company) to grow into a global biomedical group. Externally, Dr. Park also assists his colleagues as Chairman of the Korea-America Business Leaders Forum (KABLF).
Bernard K. Ham
Board Member
Mr. Bernard Ham is a highly experienced US-licensed attorney who actively advises life sciences companies in technology transactions, regulatory compliance, and business development matters. Mr. Ham is a partner at Jipyong, a major law firm in Korea with multiple offices in Asia, currently focusing his law practice on representing Korean biopharma companies in their licensing and collaboration transactions and also serves as an outside advisor to a number of biopharma companies in their business development matters. Mr. Ham was previously with large international law firms in their healthcare and pharmaceutical practices, and in addition, was previously a senior executive at Seegene, a global molecular diagnostics company, overseeing the company’s corporate strategy and business development functions.
The successful commercialization of the pCAP peptide will provide every cancer patient with dreams and hopes of complete recovery.
BL Corporation